SanegeneBio has been moving in silence for a while, which feels intentional for a company built on RNA interference. Founded in 2021 with a dual-engine footprint spanning Woburn, MA and R&D centers in Shanghai and Suzhou, this is what happens when patience, chemistry and institutional discipline sync up. On Dec 8, 2025, the volume turned up with a Series B exceeding $110M, led by a well-known industrial investor that chose anonymity over applause. In biotech, that kind of restraint usually signals confidence, not mystery.
The architecture starts with Dr. Weimin Wang, Founder and CEO, a 25+ year veteran of oligonucleotide chemistry who helped turn RNAi from science project into commercial reality at Dicerna Pharmaceuticals, Merck & Co., and Sirna Therapeutics. Paired with Dr. Shiyu Wang, Co-Founder and CSO, the leadership DNA is unmistakable. These are RNAi builders, not tourists. Add Marc Abrams, Ph.D., CTO and Head of US Operations, and Dr. Yuyan Jin, SVP of Clinical and Non-Clinical Development, and you get a team that has already absorbed the tuition of prior cycles.
The Series B stack reflects that credibility. Strategic capital came in from Eli Lilly and Company, joined by new investors Sino Biopharm, Legend Capital, Vivo Capital, Invus, SymBiosis, Guofa Capital, TruMed, Lake Bleu Capital and an international sovereign wealth fund. Returning investors Qiming Venture Partners, Northern Light Venture Capital, K2 Venture Partners, TF Capital and Oriza Holdings doubled down. With roughly $260M raised to date, including the ~$80M Tencent and YuanBio-led Series A+ in late 2023, SanegeneBio has graduated from promise to platform.
Clinically, the data is already doing the talking. SGB-3908 for hypertension completed Phase 1 with positive safety and efficacy readouts and is partnered with Innovent Biologics. SGB-9768 advanced into Phase 2 targeting IgA nephropathy and C3 glomerulopathy following strong early signals. Four programs are currently in the clinic, each designed with durability baked into the chemistry. The LEAD platform, Ligand and Enhancer Assisted Delivery, extends RNAi beyond the liver into adipose, muscle and immune cells, enabling infrequent subcutaneous dosing measured in months, not weeks.
The exclamation point came in late 2025 with a global research and licensing collaboration with Eli Lilly for metabolic disease targets, carrying up to $1.2B in potential milestones. That level of commitment does not materialize unless the science, manufacturing and execution are aligned. SanegeneBio is not chasing hype across obesity, cardiovascular disease and autoimmune nephropathies. It is engineering precision into genetic medicine, quietly compounding value while the rest of the market catches up to the signal.
Startups Startup Funding Venture Capital Series B Biotech Research Healthcare Health Tech Data Data Driven Technology Innovation Tech Ecosystem Startup Ecosystem
